Psychosis: Early Detection, Intervention and Prevention

Not Applicable

Completed

• Conditions: Severe Bipolar Disorder With Psychotic Features; Severe Major Depression With Psychotic Features; Prodromal Schizophrenia; Psychotic Disorders
• Interventions: Behavioral: Family-aided Assertive Community Treatment; Behavioral: Enhanced standard treatment

• Registration Number: NCT01597141
• Lead Sponsor: MaineHealth

Brief Summary

The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders. The intervention is Family-aided Assertive Community Treatment (FACT). The goal of the treatment is prevention of psychosis and disability. This study will assess experimentally the clinical effectiveness of this new type of mental health service. Other domains of outcome include cognitive dysfunction and functional disability.

Detailed Description

The proposed study will be part of a larger program, Portland Identification and Early Referral (PIER), under foundation, NIH and Center for Mental Health Services sponsorship, that has established a population-based system of early detection for Greater Portland, Maine. Previous and present effort has educated and trained the community-at-large and all health, education and other professionals, with the result that referrals are occurring at the expected frequency. The principal strategy is to intervene early, prior to onset, in the course of the onset of psychotic disorders to arrest the development of psychotic symptoms and functional disability. The test treatment is a specialized combination of psychoeducational multifamily group and assertive community treatment.

The project will support a team of clinical staff with the ability to: a. foster detection of prodromal disorders in the Greater Portland community by general practitioners, guidance counselors, mental health professionals and the general public; b. accurately assess individuals at high risk for psychosis; c. reliably deliver an evidence-based psychosocial and, if indicated, pharmacological treatment package using standardized methodology. The research study will test, in a randomized controlled trial, the symptomatic and functional outcome of treatment in 100 subjects ages 12 to 35 identified by that system. It will allow the analysis of key social factors contributing to psychosis and their interaction with the treatment conditions and each other.

Study Timeline

• Study Start: 2003-05
• Study First Submitted: 2012-05-09
• Study First Submitted QC: 2012-05-09
• Study First Posted: 2012-05-11
• Primary Completion: 2014-09
• Study Completion: 2014-12
• Results First Submitted: 2015-10-22
• Status Verified: 2016-01
• Results First Submitted QC: 2016-01-07
• Last Update Submitted: 2016-01-07
• Results First Posted: 2016-02-08
• Last Update Posted: 2016-02-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Prodromal psychotic symptoms
• Age 12-35
• In catchment area (greater Portland, Maine)

Read More

Exclusion Criteria

• Previous or current psychotic episode
• IQ less than 70
• Outside catchment area
• Toxic psychosis

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Family-aided Assertive Community Treatment	Family-aided Assertive Community Treatment	The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
Enhanced standard treatment	Enhanced standard treatment	In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention.

Primary Outcome Measures

Name	Time	Method
Onset of Psychosis	From date of randomization until the date of first documented onset of psychosis, assessed up to 60 months	Onset of psychosis is defined as an event--a new psychotic episode with loss of insight, meeting a score criterion of 6 for one month on the Scale of the Prodromal Syndrome (SOPS), in which full psychosis is defined as havng one score or 6, on a scale of 0 to 6, with 0 representing no psychotic symptoms, and 6 representing full psychosis on any of 5 dimensions of psychosis. The assessemnt is based on the Structrued Interview for the Prodromal Syndrome (SIPS), w widely used instrument for assessing risk of psychosis in adolescents and young adults.

Secondary Outcome Measures

Name	Time	Method
Functioning	24 months	Global Assessment of Functioning scale (GAF) at 24 months to assess functioning in symptom, role and social relationships. Global Assessment of Functioning is a widely used scale based on a Likert-keyed score assigned by an interviewer or clinician, based on a scale of 0-100, with 100 being the highest level of functioning.

Trial Locations

Locations (1)

Maine Medical Center; 🇺🇸 Portland, Maine, United States